REDWOOD CITY, Calif. — Coherus BioSciences, Inc., today announced data from the lead-in portion of the Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-targeting antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (uHCC)....
Latest News
Cold Spring Harbor, NY – Knowing exactly what’s inside a tumor can maximize our ability to fight cancer. But that knowledge doesn’t come easy. Tumors are clusters of constantly changing cancer cells. Some become common cancer variants. Others morph into deadlier, drug-resistant varieties. No one truly understands what governs this...
At a high school pep rally you would expect to see cheerleaders and mascots, but you wouldn’t expect to see a 6-year-old. On Wednesday at Grandview High school in Aurora, their guest of honor was 6-year-old Maxwell Freed. “Having him back was really special to us,” said senior class president,...
Colorectal cancer rates are rising in adults under age 50 — people who are not typically screened for such cancers. The finding, gleaned from a cancer surveillance database and published in the June issue of Cancer Epidemiology Biomarkers & Prevention, reported a 17% increase in this age group over a...
NEW YORK, NY — Columbia University scientists have been awarded a $15 million grant from the NIH’s Ultra-rare Gene-based Therapy Network to design tailor-made gene-based therapies for nine people with rare forms of amyotrophic lateral sclerosis (ALS). Gene-based therapies for ALS have potential for the approximately one in eight patients...
NEW YORK, NY — Columbia researchers have discovered a genetic variant that reduces the odds of developing Alzheimer’s disease by up to 70% and may be protecting thousands of people in the United States from the disease. The discovery of the protective variant, which appears to allow toxic forms of...
Baltimore, Maryland – A combination of two cancer drugs could be effective against malignant peripheral nerve sheath tumors (MPNSTs) — soft tissue tumors that are stubbornly resistant to chemotherapy and radiation — according to a laboratory study led by researchers at the Johns Hopkins Kimmel Cancer Center. Both drugs interfere...
MIAMI, FLORIDA – Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a ‘surprisingly high’ response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma. Based on...
According to the results of a phase 1/2 study, combination therapy with the mTOR inhibitor temsirolimus and the immunomodulatory agent lenalidomide (TEM/LEN) was feasible and demonstrated activity in heavily pretreated lymphomas, including relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). The open-label, multicenter, phase 1/2 study (ClinicalTrials.gov identifier: NCT01076543) accrued patients with R/R...
Birmingham, England – Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumour drugs as well as chemotherapy, a new trial has found. The results of the BEACON trial conducted by the Cancer Research UK Clinical Trials Unit at the...